Top

Published in:

01-12-2015 | Review

PET Radioligands for Imaging of Tau Pathology: Current Status

Authors: Yearn Seong Choe, Kyung-Han Lee

Published in: Nuclear Medicine and Molecular Imaging | Issue 4/2015

Abstract

The incidence of Alzheimer’s disease (AD), a progressive neurodegenerative disorder, continues to soar with the rapid growth of the elderly population, thus creating an enormous social and economic burden. Although disease-modifying drugs to treat AD are not yet available, several candidate drugs are in clinical trials. Most of these drugs are expected to be effective at the early stages of the disease, and therefore the early and accurate diagnosis of AD will be a critical factor in efforts to improve the prognosis of patients with AD. This review focuses on lead radioligands developed to date and their preclinical data in order to facilitate the development of tau-specific positron emission tomography radioligands that are of great interest to the scientific community.

Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–14.CrossRefPubMed

Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2:1403.CrossRefPubMed

Bowen DM, Benton JS, Spillane JA, Smith CC, Allen SJ. Choline acetyltransferase activity and histopathology of frontal neocortex from biopsies of demented patients. J Neurol Sci. 1982;57:191–202.CrossRefPubMed

Geula C, Mesulam MM. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Back KL, editors. Alzheimer disease. New York: Raven; 1994. p. 263–91.

Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999;281:1401–6.CrossRefPubMed

Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2001;12:295–300.CrossRefPubMed

Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105–15.CrossRefPubMed

Craig LA, Hong NS, McDonald RJ. Revisiting the cholinergic hypothesis in the development of Alzheimer’s disease. Neurosci Biobehav Rev. 2011;35:1397–409.CrossRefPubMed

Irie T, Fukushi K, Akimoto Y, Tamagami H, Nozaki T. Design and evaluation of radioactive acetylcholine analog for mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol. 1994;21:801–8.CrossRefPubMed

10.

Kilbourn MR, Snyder SE, Sherman PS, Kuhl DE. In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[¹¹C]methylpiperidin-4-yl propionate ([¹¹C]PMP). Synapse. 1996;22:123–31.CrossRefPubMed

11.

Namba H, Irie T, Fukushi K, Iyo M. In vivo measurement of acetylcholinesterase activity in the brain with a radioactive acetylcholine analog. Brain Res. 1994;667:278–82.CrossRefPubMed

12.

Musachio JL, Flesher JE, Scheffel U, Rauseo P, Hilton J, Mathews WB, et al. Radiosynthesis and mouse brain distribution studies of [¹¹C] CP-126,998: a PET ligand for in vivo study of acetylcholinesterase. Nucl Med Biol. 2002;29:547–52.CrossRefPubMed

13.

Bencherif B, Endres CJ, Musachio JL, Villalobos A, Hilton J, Scheffel U, et al. PET imaging of brain acetylcholinesterase using [¹¹C]CP-126,998, a brain selective enzyme inhibitor. Synapse. 2002;45:1–9.CrossRefPubMed

14.

Lee SY, Choe YS, Kim YR, Paik JY, Choi BW, Kim SE, et al. Synthesis and evaluation of 5,7-dihydro-3-(2-(1-(4-[¹⁸F]fluorobenzyl)-4-piperidinyl)ethyl)-6H-pyrrolo(3,2-f)-1,2-benzisoxazol-6-one for in vivo mapping of acetylcholinesterase. Nucl Med Commun. 2004;25:591–6.CrossRefPubMed

15.

Ryu EK, Choe YS, Park EY, Paik JY, Kim YR, Lee KH, et al. Synthesis and evaluation of 2-[¹⁸F]fluoro-CP-118,954 for the in vivo mapping of acetylcholinesterase. Nucl Med Biol. 2005;32:185–91.CrossRefPubMed

16.

Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698–712.CrossRefPubMed

17.

Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of ¹¹C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740–54.CrossRefPubMed

18.

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68:1718–25.CrossRefPubMed

19.

Zhang W, Kung MP, Oya S, Hou C’, Kung HF. ¹⁸F-Labeld styrylpyridines as PET agents for amyloid plaque imaging. Nucl Med Biol. 2007;34:89–97.CrossRefPubMed

20.

Kung HF, Choi SR, Qu W, Zhang W, Skovronsky D. ¹⁸F Stilbenes and styrylpyridines for PET imaging of Aβ plaques in Alzheimer’s disease: a miniperspective. J Med Chem. 2010;53:933–41.PubMedCentralCrossRefPubMed

21.

Clark CM, Schneider JA, Mintun MA, Bedell BJ, Beach TG, Sadowsky CH, et al. Phase III trial results for the amyoid PET imaging agent Florbetapir F 18 (¹⁸F-AV-45): imaging to histopathologic correlations in an end-of-life human subject study. Alzheimers Dement. 2010;6:S71.CrossRef

22.

Zhang W, Kung MP, Hou C, Marier DL, Kung HF. F-18 Polyethylene glycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain. Nucl Med Biol. 2005;32:799–809.CrossRefPubMed

23.

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid β in Alzheimer’s disease with ¹⁸F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.CrossRefPubMed

24.

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study. Alzheimers Dement. 2015;11:964–74.CrossRefPubMed

25.

Koole M, Lewis DM, Buckley C, Nelissen N, Vandenbulcke M, Brooks DJ, et al. Whole-body biodistribution and radiation dosimetry of ¹⁸F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med. 2009;50:818–22.CrossRefPubMed

26.

Curtis C, Gamez JE, Singh U, Sadowsky H, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287–94.CrossRefPubMed

27.

Ghoshal N, García-Sierra F, Wuu J, Leurgans S, Bennett DA, et al. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer’s disease. Exp Neurol. 2002;177:475–93.CrossRefPubMed

28.

Shah M, Catafau AM. Molecular imaging insights into neurodegeneration: focus on tau PET radiotracers. J Nucl Med. 2014;55:871–4.CrossRefPubMed

29.

Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14:114–24.CrossRefPubMed

30.

Ittner LM, Götz J. Amyloid-β and tau — a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011;12:67–72.CrossRef

31.

Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159–68.CrossRefPubMed

32.

Lee VMY, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121–59.CrossRefPubMed

33.

Chen-Plotkin AS, Lee VMY, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010;6:211–20.PubMedCentralCrossRefPubMed

34.

Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24:375–98.PubMedCentralCrossRefPubMed

35.

Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82:476–86.CrossRefPubMed

36.

Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol. 1997;273:729–39.CrossRefPubMed

37.

Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, et al. 3D structure of Alzheimer’s amyloid-β(1–42) fibrils. Proc Natl Acad Sci U S A. 2005;102:17342–7.PubMedCentralCrossRefPubMed

38.

Scheidt HA, Huster D, Rothemund I, Morgado S. Dynamics of amyloid fibrils revealed by solid-state NMR. J Biol Chem. 2012;287:2017–21.PubMedCentralCrossRefPubMed

39.

Daebel V, Chinnathambi S, Biernat J, Schwalbe M, Habenstein B, Loquet A, et al. β-Sheet core of tau paired helical filaments revealed by solid-state NMR. J Am Chem Soc. 2012;134:13982–9.CrossRefPubMed

40.

Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel ¹⁸F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420–7.CrossRefPubMed

41.

Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM. Biochemical and anatomical redistribution of tau protein in Alzheimer’s disease. Am J Pathol. 1993;143:565–78.PubMedCentralPubMed

42.

Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571–7.CrossRefPubMed

43.

Mathis CA, Klunk WE. Imaging tau deposits in vivo: progress in viewing more of the proteopathy picture. Neuron. 2013;79:1035–7.CrossRefPubMed

44.

Barrio JR, Huang SC, Cole G, Satyamurthy N, Petric A, Phelps ME, et al. PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe. J Label Compd Radiopharm. 1999;42:S194–5.

45.

Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthaylethylidene derivatives as positron emission tomography imaging probes of β-amyloid plaques in Alzheimer’s disease. J Neurosci. 2001;21:RC189.PubMed

46.

Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, et al. Comparison of the binding characteristics of [¹⁸F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology. Eur J Nucl Med Mol Imaging. 2013;40:125–32.CrossRefPubMed

47.

Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer’s disease. J Neurosci. 2005;25:10857–62.CrossRefPubMed

48.

Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer’s disease. J Alzheimers Dis. 2010;19:573–89.PubMedCentralPubMed

49.

Riss PJ, Brichard L, Ferrari V, Williamson DJ, Fryer TD, Hong YT, et al. Radiosynthesis and characterization of astemizole derivatives as lead compounds toward PET imaging of τ-pathology. Med Chem Commun. 2013;4:852–5.CrossRef

50.

Shao X, Carpenter GM, Desmond TJ, Sherman P, Quesada CA, Maria Fawaz M, et al. Evaluation of [¹¹C]N-methyl lansoprazole as a radiopharmaceutical for PET imaging of tau neurofibrillary tangles. ACS Med Chem Lett. 2012;3:936–41.PubMedCentralCrossRefPubMed

51.

Fawaz MV, Brooks AF, Rodnick ME, Carpenter GM, Shao X, Desmond TJ, et al. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer’s disease and progressive supranuclear palsy: Synthesis, preclinical evaluation, and lead selection. ACS Chem Neurosci. 2014;5:718–30.PubMedCentralCrossRefPubMed

52.

Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. [¹⁸F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2015;42:1052–61.CrossRefPubMed

53.

Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using ¹⁸F-THK5105 PET. Brain. 2014;137:1762–71.CrossRefPubMed

54.

Okamura N, Furumoto S, Harada R, Tago T, Iwata R, Tashiro M, et al. Characterization of ¹⁸F-THK-5351, a novel PET tracer for imaging tau pathology in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2014;41 Suppl 2:260.

55.

Okamura N, Furumoto S, Furukawa K, Ishiki A, Harada R, Iwata R, et al. PET imaging of tau pathology in mild cognitive impairment and Alzheimer’s disease with [¹⁸F]THK-5351. J Nucl Med. 2015;56 Suppl 3:138.

56.

Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094–108.CrossRefPubMed

57.

Hashimoto H, Kawamura K, Igarashi N, Takei M, Fujishiro T, Aihara Y, et al. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of ¹¹C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med. 2014;55:1–7.CrossRef

58.

Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, et al. A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis. 2012;31:601–12.PubMed

59.

Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457–68.PubMed

60.

Shoup TM, Yokell DL, Rice PA, Jackson RN, Livni E, Johnson KA, et al. A concise radiosynthesis of the tau radiopharmaceutical, [¹⁸F]T807. J Label Compd Radiopharm. 2013;56:736–40.CrossRef

61.

Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T808. J Alzheimers Dis. 2014;38:171–84.PubMed

62.

Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [¹⁸F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 2013;9:666–76.CrossRefPubMed

Title: PET Radioligands for Imaging of Tau Pathology: Current Status
Authors: Yearn Seong Choe
Kyung-Han Lee
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: Nuclear Medicine and Molecular Imaging / Issue 4/2015
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-015-0374-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

PET Radioligands for Imaging of Tau Pathology: Current Status

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2015

Erratum to: Changes in Skeletal Tumor Activity on 18F-choline PET/CT in Patients Receiving 223Radium Radionuclide Therapy for Metastatic Prostate Cancer

Click Reaction: An Applicable Radiolabeling Method for Molecular Imaging

NaF18-PET/CT Imaging of Secondary Hyperparathyroidism

The Alginate Layer for Improving Doxorubicin Release and Radiolabeling Stability of Chitosan Hydrogels

Isolated Central Nervous System Relapse After 10 Years in a Case of Primary Testicular Lymphoma Detected on 18F-FDG PET/CT

Prognostic Value of Metabolic Tumor Volume on 11C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma